Skip to content

Study · Randomized controlled trial · n = 115 · 2018

6 results

Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.

Fisher GA Jr, Wolin EM, Liyanage N, Pitman Lowenthal S, Mirakhur B, Pommier RF, Shaheen M, Vinik A

The oncologist16 Oct 2017Cited by 22 (Europe PMC)

PMID29038234 (opens in a new tab)PMCIDPMC5759819 (opens in a new tab)DOI10.1634/theoncologist.2017-0284 (opens in a new tab)PepBankPUB-29038234
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with NETs and carcinoid syndrome, lanreotide reduced moderate/severe symptom days versus placebo (23.4% versus 35.8%, difference -12.4, CI -20.73 to -4.07, p=.004).

    In plain wordsLanreotide reduced days with moderate or severe diarrhea and/or flushing compared with placebo.

    Peptide
    Lanreotide
    Outcome
    DecreaseDays with moderate/severe diarrhea and/or flushing
    Study

    n = 115

    Comparator
    Placebo
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    120 mg every 4 weeks · subcutaneous · 16 weeksAs given in this study (human).

    Measurements

    LS mean percentage of days with moderate/severe diarrhea and/or flushing
    23.4%
    lanreotide, double-blind phase
    LS mean percentage of days with moderate/severe diarrhea and/or flushing
    35.8%
    placebo, double-blind phase
    LS mean difference
    −12.4%
    lanreotide vs placebo; 95% CI -20.73 to -4.07
    95% CI of LS mean difference
    −20.73 to −4.07%
    lanreotide vs placebo

    Source sentences

    Summary
    During DB treatment, least square (LS) mean percentages of days with moderate/severe diarrhea and/or flushing were significantly lower for lanreotide (23.4%) versus placebo (35.8%; LS mean difference [95% confidence interval]: -12.4 [-20.73 to -4.07]; p = .004).
    1 context sentence
    Summary · context
    Adults with NETs and CS history, with/without prior somatostatin analog use, were randomized to 16 weeks' DB lanreotide 120 mg subcutaneous or placebo every 4 weeks, followed by 32 weeks' IOL lanreotide.
  2. 02HumanNon-randomized trialEfficacy outcome

    In continuing lanreotide patients, daily composite diarrhea scores improved during open-label treatment (difference -0.71, CI -1.20 to -0.22, p=.005).

    In plain wordsIn continuing lanreotide patients, diarrhea scores improved compared with the double-blind phase.

    Peptide
    Lanreotide
    Outcome
    DecreaseComposite diarrhea score during extension
    Study

    n = 56

    Comparator
    Double-blind lanreotide phase
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    120 mg every 4 weeks · subcutaneous · 32 weeksAs given in this study (human).

    Measurements

    mean difference in composite score (DB to IOL)
    −0.71 score
    diarrhea, DB lanreotide patients
    95% CI of mean difference
    −1.2 to −0.22 score
    diarrhea, DB lanreotide patients

    Source sentences

    Summary
    For DB lanreotide patients, average daily composite (frequency × severity) diarrhea scores improved significantly between DB and IOL treatment (mean difference: -0.71 [-1.20 to -0.22]; p = .005), and remained stable for diarrhea and/or flushing.
    1 context sentence
    Summary · context
    Adults with NETs and CS history, with/without prior somatostatin analog use, were randomized to 16 weeks' DB lanreotide 120 mg subcutaneous or placebo every 4 weeks, followed by 32 weeks' IOL lanreotide.
  3. 03HumanNon-randomized trialEfficacy outcome

    In continuing lanreotide patients, composite diarrhea and/or flushing scores remained stable between double-blind and open-label treatment.

    In plain wordsIn continuing lanreotide patients, combined symptom scores remained stable compared with the double-blind phase.

    Peptide
    Lanreotide
    Outcome
    No significant changeComposite diarrhea and/or flushing score during extension
    Study

    n = 56

    Comparator
    Double-blind lanreotide phase
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    120 mg every 4 weeks · subcutaneous · 32 weeksAs given in this study (human).

    Source sentences

    Summary
    For DB lanreotide patients, average daily composite (frequency × severity) diarrhea scores improved significantly between DB and IOL treatment (mean difference: -0.71 [-1.20 to -0.22]; p = .005), and remained stable for diarrhea and/or flushing.
    1 context sentence
    Summary · context
    Adults with NETs and CS history, with/without prior somatostatin analog use, were randomized to 16 weeks' DB lanreotide 120 mg subcutaneous or placebo every 4 weeks, followed by 32 weeks' IOL lanreotide.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients switching from placebo to lanreotide, diarrhea scores improved (difference -1.07, CI -1.65 to -0.49, p≤.018).

    In plain wordsDiarrhea scores improved after patients switched from placebo to lanreotide.

    Peptide
    Lanreotide
    Outcome
    DecreaseComposite diarrhea score after switch
    Study

    n = 45

    Comparator
    Prior placebo phase
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    120 mg every 4 weeks · subcutaneous · 32 weeksAs given in this study (human).

    Measurements

    mean difference in composite score (DB to IOL)
    −1.07 score
    diarrhea, DB placebo patients
    95% CI of mean difference
    −1.65 to −0.49 score
    diarrhea, DB placebo patients

    Source sentences

    Summary
    For DB placebo patients, composite scores for diarrhea, flushing, and diarrhea and/or flushing improved significantly between DB and IOL treatment (mean differences: -1.07 [-1.65 to -0.49]; -1.06 [-1.93 to -0.19]; and -2.13 [-3.35 to -0.91]; all p ≤ .018).
    1 context sentence
    Summary · context
    Adults with NETs and CS history, with/without prior somatostatin analog use, were randomized to 16 weeks' DB lanreotide 120 mg subcutaneous or placebo every 4 weeks, followed by 32 weeks' IOL lanreotide.
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients switching from placebo to lanreotide, flushing scores improved (difference -1.06, CI -1.93 to -0.19, p≤.018).

    In plain wordsFlushing scores improved after patients switched from placebo to lanreotide.

    Peptide
    Lanreotide
    Outcome
    DecreaseComposite flushing score after switch
    Study

    n = 45

    Comparator
    Prior placebo phase
    Outcome group
    Flushing · Whole body
    Studied dose
    120 mg every 4 weeks · subcutaneous · 32 weeksAs given in this study (human).

    Measurements

    mean difference in composite score (DB to IOL)
    −1.06 score
    flushing, DB placebo patients
    95% CI of mean difference
    −1.93 to −0.19 score
    flushing, DB placebo patients

    Source sentences

    Summary
    For DB placebo patients, composite scores for diarrhea, flushing, and diarrhea and/or flushing improved significantly between DB and IOL treatment (mean differences: -1.07 [-1.65 to -0.49]; -1.06 [-1.93 to -0.19]; and -2.13 [-3.35 to -0.91]; all p ≤ .018).
    1 context sentence
    Summary · context
    Adults with NETs and CS history, with/without prior somatostatin analog use, were randomized to 16 weeks' DB lanreotide 120 mg subcutaneous or placebo every 4 weeks, followed by 32 weeks' IOL lanreotide.
  6. 06HumanNon-randomized trialEfficacy outcome

    In patients switching from placebo to lanreotide, combined symptom scores improved (difference -2.13, CI -3.35 to -0.91, p≤.018).

    In plain wordsCombined diarrhea and flushing scores improved after patients switched from placebo to lanreotide.

    Peptide
    Lanreotide
    Outcome
    DecreaseComposite diarrhea and/or flushing score after switch
    Study

    n = 45

    Comparator
    Prior placebo phase
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    120 mg every 4 weeks · subcutaneous · 32 weeksAs given in this study (human).

    Measurements

    mean difference in composite score (DB to IOL)
    −2.13 score
    diarrhea and/or flushing, DB placebo patients
    95% CI of mean difference
    −3.35 to −0.91 score
    diarrhea and/or flushing, DB placebo patients

    Source sentences

    Summary
    For DB placebo patients, composite scores for diarrhea, flushing, and diarrhea and/or flushing improved significantly between DB and IOL treatment (mean differences: -1.07 [-1.65 to -0.49]; -1.06 [-1.93 to -0.19]; and -2.13 [-3.35 to -0.91]; all p ≤ .018).
    1 context sentence
    Summary · context
    Adults with NETs and CS history, with/without prior somatostatin analog use, were randomized to 16 weeks' DB lanreotide 120 mg subcutaneous or placebo every 4 weeks, followed by 32 weeks' IOL lanreotide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.